Morbidity and mortality in schizophrenia with comorbid substance use disorders.

"CONFLICT OF INTERESTS JT, EMR, HT and AT have participated in research projects funded by grants from Janssen‐Cilag and Eli Lilly to their employing institution. HT reports personal fees from Janssen‐Cilag. JT reports personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency (EMA), Eli Lilly, Janssen‐Cilag, Lundbeck and Otsuka, is a member of advisory board for Lundbeck and has received grants from the Stanley Foundation and Sigrid Jusélius Foundation. ML is a board member of Genomi Solutions ltd. and DNE Ltd., has received honoraria from Sunovion Ltd., Orion Pharma ltd. and Janssen‐Cilag, and research funding from The Finnish Medical Foundation and Emil Aaltonen Foundation. AB and JL declare no competing interests."

"This study was funded by the Finnish Ministry of Social Affairs and Health through the developmental fund for Niuvanniemi Hospital. HT was funded by Academy of Finland (grants 315969, 320107). ML was partly funded by personal grants from the Finnish Medical Foundation and Emil Aaltonen foundation. We would like to thank ms Aija Räsänen for secretarial assistance. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all of the data and the final responsibility to submit for publication. JT, EMR, HT and AT have participated in research projects funded by grants from Janssen‐Cilag and Eli Lilly to their employing institution. HT reports personal fees from Janssen‐Cilag. JT reports personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency (EMA), Eli Lilly, Janssen‐Cilag, Lundbeck and Otsuka, is a member of advisory board for Lundbeck and has received grants from the Stanley Foundation and Sigrid Jusélius Foundation. ML is a board member of Genomi Solutions ltd. and DNE Ltd., has received honoraria from Sunovion Ltd., Orion Pharma ltd. and Janssen‐Cilag, and research funding from The Finnish Medical Foundation and Emil Aaltonen Foundation. AB and JL declare no competing interests."